Reuters logo
BRIEF-Coherus Biosciences says ‍PTAB denied 4 petitions for inter partes review of Abbvie's patent
September 7, 2017 / 4:17 PM / 13 days ago

BRIEF-Coherus Biosciences says ‍PTAB denied 4 petitions for inter partes review of Abbvie's patent

Sept 7 (Reuters) - Coherus Biosciences Inc

* Coherus Biosciences provides update on ‘619 IPR institution decision

* Says ‍PTAB denied institution of all 4 petitions for inter partes review of Abbvie’s patent related to Abbvie’s Humira formulation​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below